Fullerton Neuro and Headache Ctr .
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Florin, Jack
NCT06517758: A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG.

Recruiting
3
146
Europe, Japan, US, RoW
Iptacopan, Matching Placebo
Novartis Pharmaceuticals
Generalized Myasthenia Gravis
12/26
05/32
FILIOS, NCT06869785: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

Recruiting
3
180
US
Ofatumumab approved dose, Ofatumumab new dose
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis (RMS)
12/26
05/31
ALITHIOS, NCT03650114 / 2017-004703-51: Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Calendar Jan 2028 - Dec 2028: Data from ALITHIOS trial for multiple sclerosis
Active, not recruiting
3
1882
Europe, Canada, Japan, US, RoW
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
12/27
09/28
MASTER-2, NCT03933202: A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS

Completed
N/A
291
US
Cladribine Tablets
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
11/24
11/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Florin, Jack
NCT06517758: A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG.

Recruiting
3
146
Europe, Japan, US, RoW
Iptacopan, Matching Placebo
Novartis Pharmaceuticals
Generalized Myasthenia Gravis
12/26
05/32
FILIOS, NCT06869785: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

Recruiting
3
180
US
Ofatumumab approved dose, Ofatumumab new dose
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis (RMS)
12/26
05/31
ALITHIOS, NCT03650114 / 2017-004703-51: Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Calendar Jan 2028 - Dec 2028: Data from ALITHIOS trial for multiple sclerosis
Active, not recruiting
3
1882
Europe, Canada, Japan, US, RoW
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
12/27
09/28
MASTER-2, NCT03933202: A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS

Completed
N/A
291
US
Cladribine Tablets
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
11/24
11/24

Download Options